◀ Back to ADCYAP1

ADCYAP1 — VIPR1

Pathways - manually collected, often from reviews:

• Reactome Reaction: ADCYAP1 → VIPR1 (reaction) Wenzel-Seifert et al., Biochem Pharmacol 2002, Zhang et al., Eur J Pharmacol 2003, Lambert et al., Science signaling 2008, Mitsuhashi et al., J Biol Chem 1989, Kozasa et al., Proc Natl Acad Sci U S A 1988, Baker et al., J Biol Chem 1998

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Hprd Interaction: VIPR1 — ADCYAP1 (in vitro) Payet et al., J Biol Chem 2003*

Text-mined interactions from Literome

Granoth et al., FEBS Lett 2000 : Thus, the paracrine VIP, and autocrine PACAP , related pathways leading to keratinocyte proliferation may involve VPAC(1)R/VPAC(2)R and nitric oxide/cGMP production
Tsueshita et al., J Appl Physiol 2002 : The vasorelaxant effects of aqueous PACAP- ( 1 -- 38 ) were mediated predominantly by PACAP type 1 ( PAC(1) ) receptors, whereas those of PACAP- ( 1 -- 38 ) in SSM predominantly by PACAP/vasoactive intestinal peptide type 1 and 2 ( VPAC(1)/VPAC(2) ) receptors
Yu et al., Peptides 2009 (Inflammation) : It was also found that, in ordinary condition, treatment with PAC1 agonist maxadilan induced marked increase in serum leptin, leptin : SLR ratios and resistin levels ; while in LPS induced inflammation, VPAC1 mediated much more anti-inflammatory and reversing-LPS effects of PACAP on leptin and resistin than PAC1 and VPAC2
Cho et al., J Neurosci 2012 : PACAP induced potentiation of glutamatergic synaptic responses persisted after the washout of PACAP and was blocked by the VPAC1 receptor antagonist, suggesting that VPAC1 receptors might mediate synaptic effects of PACAP in the CeL